1. Fernandes NL, Dyer RA. Anesthesia for Urgent Cesarean Section. Clin Perinatol 2019; 46(4): 785–799.
2.
Ferede YA, Nigatu YA, Agegnehu AF, et al. Incidence and associated factors of post dural puncture headache after cesarean section delivery under spinal anesthesia in University of Gondar Comprehensive Specialized Hospital, 2019, cross sectional study. International Journal of Surgery Open 2021; 33: 100348.
3.
Jasra HA, Ahmad H, Khalid S, et al. Post Dural Puncture Headache – A Comparison of 25 G and 27 G Quincke Spinal Needles in Patients Undergoing Elective Caesarean Section under Spinal Anaesthesia. JHBS M & DC 2021; 1(3): 95–98. Available from URL: https://journal.hbs.edu.pk/wp-content/uploads/2021/09/5-OA05-Post-dural-puncture-headache-a-comparison-of-25-G-and-27-G-Quincke-spinal-needles.pdf.
4.
Lu YY, Wang HY, Lin Y, et al. The value of changing position in the detection of CSF leakage in spontaneous intracranial hypotension using Tc-99m DTPA scintigraphy: two case reports. Iran J Radiol 2012; 9(3): 150–153.
5.
Maronge L, Bogod D. Complications in obstetric anaesthesia. Anaesthesia 2018; 73(Suppl. 1): 61–66.
6.
Jabbari A, Alijanpour E, Mir M, et al. Post spinal puncture headache, an old problem and new concepts: review of articles about predisposing factors. Caspian J Intern Med 2013; 4(1): 595–602.
7.
Hatfalvi B. The Dynamics of Post-Spinal Headache. Headache 1977; 17(2): 64–66.
8.
Mohamed ZE, Selim MF. Rationale of modified paraspinous/paramedian technique for spinal anesthesia in preven-tion of post dural puncture headache after cesarean section. Anaesth Pain Intensive Care 2021; 25(4): 487–493.
9.
Kaukinen S, Kaukinen L, Kannisto K, et al., eds. The prevention of headache following spinal anaesthesia. Ann Chir Gynaecol 1981; 70(3): 107–111.
10.
Phillips WJ, Ostrovsky O, Galli RL, et al. Relief of acute migraine headache with intravenous oxytocin: report of two cases. J Pain Palliat Care Pharmacother 2006; 20(3): 25–28.
11.
Kesmati M, Haghighi N, Zadkarami M. [Study of Interaction Between Oxytocin and Opioid System in Locus Coeruleus on Acute Pain in the Rat]. IJEM 2007; 9(2): 171–175 (in Persian).
12.
Wang Y-L, Yuan Y, Yang J, et al. The interaction between the oxytocin and pain modulation in headache patients. Neuropeptides 2013; 47(2): 93–97.
13.
Tzabazis A, Mechanic J, Miller J, et al. Oxytocin receptor: expression in the trigeminal nociceptive system and poten-tial role in the treatment of headache disorders. Cephalalgia 2016; 36(10): 943–950.
14.
Caughey AB, Cahill AG, Guise J-M, et al. Safe prevention of the primary cesarean delivery. Am J Obstet Gynecol 2014; 210(3): 179–193.
15.
Matsuura T, Motojima Y, Kawasaki M, et al. [Relationship Between Oxytocin and Pain Modulation and Inflammation]. J UOEH 2016; 38(4): 325–334 (in Japanese).
16.
Rash JA, Aguirre-Camacho A, Campbell TS. Oxytocin and pain: a systematic review and synthesis of findings. Clin J Pain 2014; 30(5): 453–462.
17.
Tracy LM, Georgiou-Karistianis N, Gibson SJ, et. al. Oxytocin and the modulation of pain experience: implications for chronic pain management. Neurosci Biobehav Rev 2015; 55: 53–67.
18.
Reeta K, Mediratta PK, Rathi N, et. al. Role of kappa- and delta-opioid receptors in the antinociceptive effect of oxytocin in formalin-induced pain response in mice. Regul Pept 2006; 135(1–2): 85–90.
19.
Witt DM, Winslow JT, Insel TR. Enhanced social interactions in rats following chronic, centrally infused oxytocin. Pharmacol Biochem Behav 1992; 43(3): 855–861.
20.
Uvnäs-Moberg K, Bruzelius G, Alster P, et al. Oxytocin increases and a specific oxytocin antagonist decreases pain threshold in male rats. Acta Physiol Scand 1992; 144(4): 487–488.
21.
Boll S, De Minas AA, Raftogianni A, et al. Oxytocin and pain perception: from animal models to human research. Neuroscience 2018; 387: 149–161.
22.
Russo R, D’Agostino G, Raso GM, et al. Central administration of oxytocin reduces hyperalgesia in mice: implication for cannabinoid and opioid systems. Peptides 2012; 38(1): 81–88.
23.
Yang J. Intrathecal administration of oxytocin induces analgesia in low back pain involving the endogenous opiate peptide system. Spine 1994; 19(8): 867–871.
24.
Krause DN, Warfvinge K, Haanes KA, et al. Hormonal influences in migraine – interactions of oestrogen, oxytocin and CGRP. Nat Rev Neurol 2021; 17(10): 621–633.
25.
Aghakhani K, Soltani S, Memarian A, et al. The Relationship between Demographic Indicators and Mortality Rate of Covid-19 Disease Comparatively and Retrospectively in Different Waves of Covid-19 Disease in Iran. J Exp Clin Med 2022; 39(4): 1038–1042.
26.
Besharat SAN, Dadashzadeh N, Talaie R, et al. Clinical and Demographic Characteristics of Patients with COVID-19 Who Died in Modarres Hospital. Open Access Maced J Med Sci 2020; 8(T1): 144–149.
27.
Barzegar A, Ghadipasha M, Rezaei N, et al. New hope for treatment of respiratory involvement following COVID-19 by bromhexine. J Nephropharmacol 2021; 10(2): e11.
28.
Tabatabaii SA, Soltani P, Khanbabaee G, et al. SARS Coronavirus 2, Severe Acute Respiratory Syndrome, and Middle East Respiratory Syndrome in Children: A Review on Epidemiology, Clinical Presentation, and Diagnosis. Arch Pediatr Infect Dis 2020; 8(4): e104860.
29.
Zakeri R, Kellner JS, Rahimi MM. Drug therapy in hospitalized patients with very severe symptoms following COVID-19. J Nephropharmacol 2020; 9(2): e21.
30.
Lotfi B, Farshid S, Dadashzadeh N, et al. Is Coronavirus Disease 2019 (COVID-19) Associated with Renal Involvement? A Review of Century Infection. Jundishapur J Microbiol 2020; 13(4): e102899.
31.
Diep PT, Talash K, Kasabri V. Hypothesis: Oxytocin is a direct COVID-19 antiviral. Med Hypotheses 2020; 145: 110329.
32.
Diep PT, Buemann B, Uvnäs-Moberg K. Oxytocin, A Possible Treatment for Covid-19? Everything to Gain, Nothing to Lose. Clin Neuropsychiatry 2020; 17(3): 192–193.